Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The firm, in its preview of Q1 earnings for 36 commercial-stage companies in its biotechnology coverage, revised some estimates to account for recent news flow, company commentary, and/or prescription trends.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $1,081 from $1,150 at Morgan Stanley
- Regeneron Faces Financial Challenges Amid Co-Pay Assistance Funding Shortfall, Prompting Sell Rating
- Regeneron price target lowered to $925 from $950 at Oppenheimer
- Needham healthcare analysts hold analyst/industry conference call
- Gilead, Regeneron have most theoretical PDUFA date risk, says BofA